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Abstract
Purpose CAM2028, a vehicle that forms a bioadhesive lipid
barrier when applied to the oral mucosa, was developed as a
carrier system for local delivery of benzydamine, an NSAID
used for pain relief in oral mucositis. This trial compared the
analgesic effect of CAM2028 plus benzydamine (CAM2028-
benzydamine) with unmedicated CAM2028 (CAM2028-
control) for the treatment of oral mucositis in patients with
head-and-neck cancer.
Methods Thirty-eight study participants were enrolled during
their 3rd to 4th week of radiation therapy. Participants were
required to have symptomatic oral mucositis (WHO Grade 2
or above) at screening and pain scores of at least 6 on an 11-
point Likert scale at screening and on each day before treat-
ment with study medication. After undergoing radiation, pa-
tients were administered a single dose of CAM2028-control or
CAM2028-benzydamine 2 days apart, in a randomized cross-
over fashion. Pain was assessed over the following 8 h.
Results With both treatments, patients experienced a mean
40 % decrease in pain intensity at 6 h (the primary study
endpoint). Both treatments resulted in significant pain relief
within 5 min of application that was evident during the entire
8-h assessment period. There was no difference in pain relief
between the two interventions at any time point. Both treat-
ments were safe and well tolerated.
Conclusions CAM2028-benzydamine and CAM2028-
control were both efficacious in reducing pain in patients with
oral mucositis related to radiation therapy for head-and-neck
cancer. Analgesic effects of bothmedications were immediate,
clinically significant, and persistent for up to 8 h.
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Introduction
Oral mucositis has emerged as one of the most troublesome
consequences of current high-intensity cancer treatment regi-
mens. High-grade (grade 3 or 4) oral mucositis affects virtu-
ally 100 % of patients who undergo high-dose radiation
therapy for head-and-neck cancer and is a major limiting
factor for advanced chemoradiation regimens [1, 2]. Oral
mucositis has a significant negative effect on the patient
experience of cancer therapy, contributing to difficulty eating
and drinking, weight loss, fatigue, pain, sleep deprivation, and
functional impairment [3]. Intolerable oral mucositis is the
primary cause of unplanned treatment breaks in head-and-
neck cancer, limiting the efficacy of aggressive treatment
regimens and negatively affecting treatment outcomes [4, 5].
Oral mucositis is associated with greater health care re-
source use and higher economic costs due to patients’ need for
supportive care, parenteral or enteral nutrition, opioid analge-
sics, and hospitalization [6, 7]. According to one analysis in
patients with head-and-neck cancer, oral mucositis was asso-
ciated with an additional treatment cost of $1,700 to $6,000,
depending on the grade [2]. In another study, high-grade oral
mucositis in patients with head-and-neck cancer was associ-
ated with an incremental treatment cost of $17,000 (in 2003–
2005), largely driven by inpatient hospitalization to support
alimentation [8].
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Recommended evidence-based management of oral muco-
sitis in patients with head-and-neck cancer consists of
implementing an oral care protocol, regularly assessing pa-
tients for oral symptoms, and empiric short-term analgesics [1,
9, 10]. Gentle brushing and flossing and the use of bland oral
rinses are common features of oral care protocols. Although a
number of interventions are available to relieve pain associat-
ed with oral mucositis, there is currently a lack of well-
supported therapies. According to a recent Cochrane review,
[11] randomized clinical trials of oral mucositis treatments are
few and offer little clinical guidance. The existing evidence
has not shown mouthwashes containing analgesics or antisep-
tics to be superior to placebo or to unmedicated preparations.
Behavioral approaches—relaxation and imagery or hypno-
sis—were also not superior to control treatments. There is a
need for effective, rapid-acting treatment that can be easily
deployed in the clinic as needed.
Benzydamine is among the agents frequently recommend-
ed for pain relief in oral mucositis in patients undergoing
moderate-dose radiation therapy for head-and-neck cancer
[1, 9, 10]. Benzydamine is a nonsteroidal antiinflammatory
drug with a long history of safe use in patients. Results of
clinical trials of benzydamine in oral mucositis have been
mixed: two studies showed no greater effects on pain than
placebo [11] but one trial suggests it is effective in preventing
mouth ulcers and delaying the use of systemic analgesics
following radiation for head-and-neck cancer [12]. The cur-
rently available oromucosal benzydamine products have a
short duration of effectiveness and need to be administered
every 1.5 to 3 h.
Development of investigational formulation
CAM2028-benzydamine was developed as a lipid-based drug
carrier system for local and extended delivery of benzydamine
in the oral cavity. After application to the oral mucosa, phos-
pholipid and triglyceride lipid components of the formulation
spread in the oral cavity and self-assemble with a trace volume
of aqueous fluid at the mucosal surface to form a bioadhesive
liquid crystalline lining protecting the sore and inflamed
mucosa, including exposed nerve endings (Fig. 1). The liquid
crystalline film formation occurs by molecular self-assembly
of the lipid components and ambient water molecules present
in saliva, and does not involve any chemical reaction. The film
adheres to the palate, the inside of the cheeks, gums, and the
rim of the tongue. In the formulation containing benzydamine,
the drug was slowly released into the oral mucosa, with the
aim of conferring rapid-onset and prolonged analgesia.
Additional effects of the bioadhesive lipid formulation may
include lubrication and mechanical protection of the sore
mucosa and possibly a moistening effect.
Patients and methods
CAM2028, with and without benzydamine, was evaluated in
a crossover, double-blind, placebo-controlled, single-dose,
randomized, proof-of-concept trial in head-and-neck cancer
patients receiving radiotherapy. The study was conducted at
five oncology centers in Bulgaria. The protocol and the state-
ment of informed consent were approved in Bulgaria by an
Independent Ethics Committee. The trial was conducted in
accordance with the Declaration of Helsinki and its revisions
as well as with the valid local and national laws of Bulgaria;
with the International Conference on Harmonisation (ICH)
Harmonised Tripartite Guideline for Good Clinical Practice
(E6) issued in July 1996; and with the relevant European
Commission Directives. All patients gave written informed
consent prior to enrollment.
Study participants were male or female patients, at least
18 years of age, undergoing outpatient radiation therapy for
newly diagnosed head-and-neck cancer. At screening, all pa-
tients had undergone radical or postoperative radiotherapy to a
significant part of clinically visible oral and/or pharyngeal
mucosa at two or more anatomic sites. The trial began during
weeks 3 to 4 of radiotherapy and took place over a maximum
duration of 12 days. After a screening period of up to 7 days,
treatment was randomly assigned; at this point, patients must
have received at least one third of the planned total dosage of
radiation. At screening, participants were required to exhibit
symptomatic oral mucositis (WHO grade 2 or above). Pain
scores of at least 6 on a Likert scale of 0 to 10 were required at
screening and before each treatment. Clinically relevant ex-
clusion criteria were pregnancy or breastfeeding, known con-
traindications or hypersensitivity to the trial drug or other
NSAIDs, immunocompromised, hepatitis A or B infection,
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The present report describes the development and pilot-
testing of a new formulation of benzydamine designed to
extend its analgesic effects for a sustained period. The pilot
study described herein, a randomized crossover trial in pa-
tients with head-and-neck cancer, had the unexpected result
that the formulation itself had a prolonged analgesic effect,
regardless of whether it contained benzydamine or was un-
medicated. Based on these and other data, and by virtue of its
mechanical mode of action, the formulation, CAM2028-con-
trol (episil®, Camurus) has recently received FDA and EU
approvals as a medical device for the management of pain in
oral mucositis.
The present study was conducted with the primary objec-
tive of testing the analgesic effect of CAM2028 with
benzydamine compared with CAM2028 without
benzydamine (the FDA approved prescription formulation of
episil®) over an 8-h period. An additional objective was to
assess the safety and tolerability of a single dose of the new
formulation.
and prior chemotherapy, immunotherapy, or radiation to the
upper airways.
Study design and procedures
Patients were administered the trial medication after under-
going radiotherapy. The investigational medication consisted
of the oromucosal solution CAM2028 containing
benzydamine 28.2 mg/mL. The comparison treatment was
CAM2028-control. One milliliter of either the study med-
ications was applied to the oral mucosa using a syringe,
and patients were instructed to swirl the medication
around in the mouth for approximately 15 s and then spit
out any residual medication. The procedure was repeated
after 5 min.
Concomitant use of any oromucosal medication was not
permitted from 3 days before dosing on Day 1 until the final
evaluation on Day 5. This prohibition included oromucosal
analgesics, anti-inflammatories, antimicrobials, and muco-
protective agents. Also prohibited were systemic anti-
inflammatories, analgesics, and drugs that may affect the
process of oral mucositis, including growth factors, vitamins,
and newly introduced steroids. Immediate-release paraceta-
mol, opioids, and opiates were permitted as rescue medica-
tion. Eating and drinking hot beverages was not allowed until
3 h after drug administration.
Evaluations
On each treatment day, oromucosal pain was assessed by the
patient using an 11-point Likert scale (0=no pain, 10=worst
possible pain). Patients recorded their pain scores before dos-
ing and at 5 and 30 min and 1, 2, 3, 6, and 8 h post-dose. After
the initial 3-h assessment, patients were allowed to leave the
hospital with a diary for recording pain scores at 6 and 8 h.
Adverse events were to be recorded throughout the study
period, not just on treatment days. Symptomatic changes were
elicited from the patient in a non-leading manner at each visit.
Clinically relevant laboratory values or pathological changes,
as determined by the investigator, were also to be recorded as
adverse events. Investigators were to record information on an
Adverse Event Report Form, including severity grading, res-
olution, and relationship to study medication as determined by
the investigator. An adverse event was defined as treatment-
emergent if it had onset or worsened after the first use of study
medication and no more than 1 day after the last use.
Statistical methods
A total of 38 patients were enrolled with the aim of a final
sample of 32 evaluable patients. As this was a pilot study,
sample size was determined empirically. The primary efficacy
Fig. 1 Mechanism of action of CAM2028. After application to the oral mucosa, phospholipid and triglyceride lipid components self-assemble with a
trace volume of water (saliva) to form a bioadhesive and protective liquid crystalline lining of the oral mucosa
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Eligibility was confirmed at the screening visit, a maximum of
7 days before the first treatment visit. Patients were treated
with randomized study medication on Treatment Days 1 and
3, and returned for a final follow-up evaluation on Day 5. At
the first treatment visit, each patient was randomly allocated to
one of two sequences: CAM2028-benzydamine (Day 1)
followed by CAM20208-control (Day 3), or CAM2028-
control followed by CAM2028-benzydamine. Patients were
assigned a random number and received trial medication sent
from the study coordinating center with the corresponding
number. The list of random numbers was generated at the
coordinating center using the permuted bloc method based on
SAS® for Windows (SAS Institute Inc., Cary, NC, USA).
Treatment allocation was concealed from the investigators,
staff at the trial sites, trial monitors, data analysts and man-
agers, and patients.
endpoint was the pain intensity difference (PID), calculated as
the change in the Likert pain scale from baseline to 6 h after
administration of study medication. Secondary outcome mea-
sures were the PID at other time intervals, peak pain (maxi-
mum Likert score on each treatment day), and the area
under the curve (AUC) of the PID. The last observation
carried forth (LOCF) method was used to replace miss-
ing pain score data from the same day. The primary
efficacy endpoint was evaluated using the mixed effects
analysis of covariance (ANCOVA) model on ranks. The
model included effects for treatment, center, sequence,
period, patient, and baseline Likert pain score.
Secondary endpoints were analyzed in the same manner.
Analyses were planned on the safety data set (patients
who received at least one dose of study medication), the
full data set (patients who provided data on the primary
efficacy variable for both treatments) and the per-
protocol data set (patients who completed the trial with
no protocol deviations). Analyses were conducted using
Results
Patient characteristics and disposition
Thirty-eight patients were randomly assigned to treatment,
and all completed the trial. Twenty patients were assigned to
receive CAM2028-benzydamine on Day 1 and CAM2028-
control on Day 3, and 18 patients received the treatments in
the opposite order. All were included in the safety population
and the full data set. Three patients were not included in the
per-protocol set because they had a baseline pain score lower
than 6 on the second treatment visit (when all three were
scheduled to receive CAM2028-benzydamine) and three
others had minor protocol violations in recording their pain
scores. The per-protocol set consisted of 19 patients who
received the CAM2028-benzydamine first and 13 who re-
ceived CAM2028-control first. All patients took all doses of
study medication.
Demographic characteristics did not differ between the two
treatment groups, with the exception that women were over-
represented in the group receiving placebo first (5 versus 1).
Patients were a median age of 52 years (range 32 to 73), 32
patients (84.2 %) were male, and all were of Caucasian
ethnicity. Mean body mass index was 21.5 kg/m2. Nearly half
of the participants were sporadic consumers of alcohol
(47.4 %), rather than non-drinkers (26.3 %) or regular drinkers
(26.3 %). Most were current smokers (42.1 %) or ex-smokers
(42.1 %). Patients were screened for study participation at a
median of about 6 weeks following the diagnosis of head-and-
neck cancer (range 9 days to >17 weeks).
Treatment efficacy
We present results of the analysis of treatment efficacy for the
per-protocol data set; results in the full patient population did
not differ. Themean pain intensity difference at 6 h was 2.5 for
CAM2028-benzydamine and 2.2 for CAM2028-control (i.e.,
patients experienced an average 2-plus-point decline in pain
intensity from baseline to 6 h after treatment). Mean pain
intensity ratings decreased by about 40 %, from a baseline
of 6.5 (CAM2028-benzydamine) or 6.4 (CAM2028-control)
to 4.6 (both treatments) already within 5 min of study medi-
cation application and remained at this level or lower through-
out the 8 h of observation (Table 1, Fig. 2). At no time did
mean pain ratings or PID differ statistically between the two
treatments.
The mean AUC of pain intensity over time did not differ
between the two treatments. The mean peak PID was 2.8 for
CAM2028-benzydamine and 2.7 for CAM2028-control. All
of the analyses of pain intensity outcomes showed a statisti-
cally significant clinical center effect, with one center
reporting larger PID values than others. The data do not
suggest any explanation for this difference.
Safety and tolerability
Four patients experienced seven treatment-emergent adverse
events. None were considered severe, and none were judged
to be related to study medication. Two patients experienced
nausea or vomiting on CAM2028-benzydamine, one on
CAM2028-control, and one on both treatments. Upper respi-
ratory tract infection and hemoptysis each occurred in 1 pa-
tient who received the CAM2028-benzydamine.
Regarding rescue medication, only paracetamol was used
in a total of 8 patients (21 %) during the course of the
treatment period. None of the patients used opioids as rescue
medication.
Table 1 Patient evaluations of pain intensity on an 11-point Likert scale,
before and at selected time points after administration of CAM2028-
benzydamine or CAM2028-control (per-protocol population, n=32)
Before
dosing
5 min 1 h 6 h 8 h
CAM2028-benzydamine
Mean±SD 6.5±0.80 4.6±1.60 4.1±1.98 4.0±2.06 4.2±2.03
Median 6.0 4.5 4.0 4.0 4.0
Range 6–8 2–8 1–8 1–8 1–8
CAM2028-control
Mean±SD 6.4±0.72 4.6±1.54 3.9±2.0 4.3±2.23 4.4±2.09
Median 6 4 4 4 4
Range 6–8 1–8 0–8 0–9 0–9
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SAS® release 8.2.
Discussion
This randomized trial set out to compare the effects
CAM2028-benzydamine and CAM2028-control in patients
who experienced oral pain while undergoing radiation therapy
for head-and-neck cancers. Both study medications had an
immediate and clinically significant pain-relieving effect with-
in 5 min of application and that analgesic effect was main-
tained for up to 8 h. We found that the two treatments had
similar effects in reducing pain, due to the efficacy of the
bioadhesive and physically protective mechanical barrier,
which we had not predicted. The two treatments did not differ
on the main outcome measure, PID from baseline, or on any
other measure of pain.
The similar treatment effects of CAM2028 with or without
benzydamine suggest that benzydamine did not contribute
additionally to the reduction of oral mucositis pain compared
with the unmedicated CAM2028-control. Although no further
effects were seen with benzydamine, it cannot be excluded
that benzydamine has a role in the management of oral mu-
cositis, but this would require further investigation in repeat
dose studies. However, the present results obtained with single
doses of CAM2028, with and without benzydamine, suggest
that the observed analgesic effect is mainly due to the effective
mechanical protection of the oral mucosal surfaces provided
by the in situ barrier-forming lipid solution. This lipid barrier
covers and isolates the sore mucosa and exposed nerve end-
ings from external irritation. Thus, CAM2028 offers a unique
approach for treating local pain associated with oral mucositis
that does not interfere with the use of other therapies and that,
additional experience suggests, may be used with additive
effects. In a preliminary study in patients undergoing high-
dose chemotherapy for autologous stem-cell transplantation,
CAM2028 combined with cryotherapy resulted in fewer and
less severe occurrences of oral mucositis compared with cryo-
therapy alone [14]. Unlike cryotherapy alone, CAM2028 also
spared patients the need for total parenteral nutrition and for
opioids for pain relief.
At present, there are few other effective treatments for pain
associated with oral mucositis. The most widely prescribed
topical therapy is a pharmacist-compounded mouthwash gen-
erally called “magic” or “miracle mouthwash” [15, 16]. There
is no standard formulation for this mouthwash, but the most
popular formulation consists of viscous lidocaine, diphenhy-
dramine, and an antacid. Although its widespread use suggests
clinicians perceive it to be effective, there is no clinical trial
evidence supporting the efficacy of compounded mouthwash
in relieving pain associated with oral mucositis [11], and one
trial found it no more effective than salt and soda [17].
Because lidocaine-containing products can cause numbness,
patients are advised to avoid eating or performing oral hygiene
measures after using these products to avoid accidental trauma
to oral tissues [9]. Lidocaine can also dampen the gag reflex,
placing the patient at risk for aspiration. The diphenhydramine
component of the mouthwash formulation can exacerbate the
xerostomia that patients with oral mucositis frequently
experience.
Based on the results of this study in 38 cancer patients with
oral mucositis while undergoing radiation treatment for head-
and-neck cancer, it is concluded that CAM2028 resulted in
immediate and significant pain relief with a duration that was
maintained for up to 8 h. The reduction of pain was similar
between both CAM2028 treatments, suggesting that
benzydamine did not contribute additionally to the reduction
of oral mucositis pain compared with the CAM2028-control.
Both CAM2028 treatments were found to be safe and well
tolerated in this group of patients.
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Fig. 2 Patient evaluations - pain intensity (11 point Likert scale) versus
time after application of study medication at time 0 (per-protocol set,
N=32)
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Based on subsequent experience, administration of the
currently approved CAM2028 product (episil®, Camurus)
differs from that described in this study. A phase 2 clinical
trial showed that upon application, the formulation takes less
than 1min to form a bioadhesive and protective lining and that
a smaller quantity of CAM2028 is sufficient to provide effec-
tive coverage of oromucosal surfaces, rather than the 1 mL
used in the present study, where patients were informed to spit
out excess solution [13]. The current product (episil®) label-
ing instructs patients to spray a 0.15-mL metered dose of the
liquid into the oral cavity 1 to 3 times (delivering a quantity
ranging from 0.15 to 0.45 mL) and to allow 5 min for the
bioadhesive barrier to form. They are then able to eat or drink
immediately, rather than waiting several hours.
The authors have full control of all primary data and have agreed to allow
the journal to review the data if requested.
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